Tobevibart

N/A

Report date: 2026/03/07 20:00:27

Base Information

Drug NameTobevibart
Drug Alias NameVIR-3434BRII-877
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionHBsAg inhibitorsVirus internalization inhibitors
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis D, ChronicHepatitis, Viral, HumanHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesVir Biotechnology Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesVir Biotechnology IncUniversity Health Network (Uhn)Brii Biosciences (Beijing) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsHepatitis D, ChronicHepatitis, Viral, HumanHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A